Vitekta OverviewElvitegravir (EVG) is an integrase inhibitor used to treat HIV infection. It was developed by the pharmaceutical company Gilead Sciences, which licensed EVG from Japan Tobacco in March 2008. The drug gained approval by the U.S. Food and Drug Administration on August 27, 2012 for use in adult patients starting HIV treatment for the first time as part of the fixed dose combination known as Stribild. ...
Read more Vitekta Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Elvitegravir
Recent Vitekta Forums:Be the first to start a discussion about this drug.
Possible Dosages for this and Related Drugs:
- Tablet: 150mg, 85mg
NDC Database Records for Vitekta: (2 results)Sorted by National Drug Code
- 61958-1301 Vitekta 85 mg Oral Tablet, Film Coated by Gilead Sciences, Inc.
- 61958-1302 Vitekta 150 mg Oral Tablet, Film Coated by Gilead Sciences, Inc.
Other drugs which contain Elvitegravir or a similar ingredient: (4 results)
- COBICISTAT + ELVITEGRAVIR + EMTRICITABINE + TENOFOVIR
- GENVOYA Elvitegravir + Cobicistat + Emtricitabine + Tenofovir Alafenamide3 discussions
- STRIBILD Cobicistat + Elvitegravir + Emtricitabine + Tenofovir1 discussion